Associated Papers
Tumor-acquired somatic mutation affects conformation to abolish ABCG2-mediated drug resistance.
Gose T et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy, 2024
How Cryo-EM Has Expanded Our Understanding of Membrane Transporters.
Baril SA et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2023
Structures of ABCG2 under turnover conditions reveal a key step in the drug transport mechanism.
Yu Q et al.
Nature Communications, 2021
Medically Important Alterations in Transport Function and Trafficking of ABCG2.
Homolya L
International Journal of Molecular Sciences, 2021
ABCG2 Overexpression Contributes to Pevonedistat Resistance.
Kathawala RJ et al.
Cancers, 2020
Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance.
Wu ZX et al.
Cancers, 2020
Residues contributing to drug transport by ABCG2 are localised to multiple drug-binding pockets.
Cox MH et al.
The Biochemical Journal, 2018
Biochemical studies on the structure-function relationship of major drug transporters in the ATP-binding cassette family and solute carrier family.
Hong M
Advanced Drug Delivery Reviews, 2017
A-803467, a tetrodotoxin-resistant sodium channel blocker, modulates ABCG2-mediated MDR in vitro and in vivo.
Anreddy N et al.
Oncotarget, 2015
Linsitinib (OSI-906) antagonizes ATP-binding cassette subfamily G member 2 and subfamily C member 10-mediated drug resistance.
Zhang H et al.
The International Journal of Biochemistry & Cell Biology, 2014
Masitinib antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance.
Kathawala RJ et al.
International Journal of Oncology, 2014
Regulation of the function of the human ABCG2 multidrug transporter by cholesterol and bile acids: effects of mutations in potential substrate and steroid binding sites.
Telbisz Á et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2014
Human ABC transporter ABCG2/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics.
Noguchi K et al.
Pharmacogenomics and Personalized Medicine, 2014
Predicting substrates of the human breast cancer resistance protein using a support vector machine method.
Hazai E et al.
Bmc Bioinformatics, 2013
Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells.
Wu CP et al.
Biochemical Pharmacology, 2013
The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2.
Sen R et al.
Molecular Cancer Therapeutics, 2012
GW583340 and GW2974, human EGFR and HER-2 inhibitors, reverse ABCG2- and ABCB1-mediated drug resistance.
Sodani K et al.
Biochemical Pharmacology, 2012
Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression.
Nakanishi T et al.
Chinese Journal of Cancer, 2012
Arginine 482 to glycine mutation in ABCG2/BCRP increases etoposide transport and resistance to the drug in HEK-293 cells.
Eddabra L et al.
Oncology Reports, 2012
Analysis of the effect of the bovine adenosine triphosphate-binding cassette transporter G2 single nucleotide polymorphism Y581S on transcellular transport of veterinary drugs using new cell culture models.
Real R et al.
Journal of Animal Science, 2011
Pharmacogenetics of genes across the doxorubicin pathway.
Jamieson D et al.
Expert Opinion on Drug Metabolism & Toxicology, 2011
Prognostic value of the multidrug resistance transporter ABCG2 gene polymorphisms in Chinese patients with de novo acute leukaemia.
Wang F et al.
European Journal of Cancer (oxford, England : 1990), 2011
Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.
Shi Z et al.
Cancer Research, 2011
Recombinant synthesis of human ABCG2 expressed in the yeast Saccharomyces cerevisiae: an experimental methodological study.
Jacobs A et al.
The Protein Journal, 2011
The ABCG2 transporter and its relations with the pharmacokinetics, drug interaction and lipid-lowering effects of statins.
Hu M et al.
Expert Opinion on Drug Metabolism & Toxicology, 2011
Variation and evolution of the ABC transporter genes ABCB1, ABCC1, ABCG2, ABCG5 and ABCG8: implication for pharmacogenetics and disease.
Silverton L et al.
Drug Metabolism and Drug Interactions, 2011
Transmembrane helices 1 and 6 of the human breast cancer resistance protein (BCRP/ABCG2): identification of polar residues important for drug transport.
Ni Z et al.
American Journal of Physiology. Cell Physiology, 2010
ABCG2 transports and transfers heme to albumin through its large extracellular loop.
Desuzinges-Mandon E et al.
The Journal of Biological Chemistry, 2010
Role of basic residues within or near the predicted transmembrane helix 2 of the human breast cancer resistance protein in drug transport.
Cai X et al.
The Journal of Pharmacology and Experimental Therapeutics, 2010
Key Role of Human ABC Transporter ABCG2 in Photodynamic Therapy and Photodynamic Diagnosis.
Ishikawa T et al.
Advances in Pharmacological Sciences, 2010
Major SNP (Q141K) variant of human ABC transporter ABCG2 undergoes lysosomal and proteasomal degradations.
Furukawa T et al.
Pharmaceutical Research, 2009
Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy.
Noguchi K et al.
Advanced Drug Delivery Reviews, 2009
Quality control of human ABCG2 protein in the endoplasmic reticulum: ubiquitination and proteasomal degradation.
Wakabayashi-Nakao K et al.
Advanced Drug Delivery Reviews, 2009
Is ATP binding responsible for initiating drug translocation by the multidrug transporter ABCG2?
McDevitt CA et al.
The Febs Journal, 2008
Effect of cysteine mutagenesis on the function and disulfide bond formation of human ABCG2.
Liu Y et al.
The Journal of Pharmacology and Experimental Therapeutics, 2008
Human ABC transporters ABCG2 (BCRP) and ABCG4.
Koshiba S et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2008
Effects of drug efflux proteins and topoisomerase I mutations on the camptothecin analogue gimatecan.
Gounder MK et al.
Investigational New Drugs, 2008
Ubiquitin-mediated proteasomal degradation of non-synonymous SNP variants of human ABC transporter ABCG2.
Nakagawa H et al.
The Biochemical Journal, 2008
Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors.
Lemos C et al.
British Journal of Cancer, 2008
Membrane cholesterol selectively modulates the activity of the human ABCG2 multidrug transporter.
Telbisz A et al.
Biochimica Et Biophysica Acta, 2007
ATP-binding cassette, subfamily G (ABCG family).
Kusuhara H et al.
Pflugers Archiv : European Journal of Physiology, 2007
Re-evaluation and functional classification of non-synonymous single nucleotide polymorphisms of the human ATP-binding cassette transporter ABCG2.
Tamura A et al.
Cancer Science, 2007
Purification of breast cancer resistance protein ABCG2 and role of arginine-482.
Pozza A et al.
Cellular and Molecular Life Sciences : Cmls, 2006
Modulation of the function of the multidrug resistance-linked ATP-binding cassette transporter ABCG2 by the cancer chemopreventive agent curcumin.
Chearwae W et al.
Molecular Cancer Therapeutics, 2006
Functional validation of the genetic polymorphisms of human ATP-binding cassette (ABC) transporter ABCG2: identification of alleles that are defective in porphyrin transport.
Tamura A et al.
Molecular Pharmacology, 2006
The nature of amino acid 482 of human ABCG2 affects substrate transport and ATP hydrolysis but not substrate binding.
Ejendal KF et al.
Protein Science : a Publication of the Protein Society, 2006
ATP-binding cassette transporter G2 mediates the efflux of phototoxins on the luminal membrane of retinal capillary endothelial cells.
Asashima T et al.
Pharmaceutical Research, 2006
The role of the human ABCG2 multidrug transporter and its variants in cancer therapy and toxicology.
Cervenak J et al.
Cancer Letters, 2006
Genetic polymorphisms of human ABC transporter ABCG2: development of the standard method for functional validation of SNPs by using the Flp recombinase system.
Tamura A et al.
Journal of Experimental Therapeutics & Oncology, 2006